EMC7

Across TCGA pan-cancer cohorts, EMC7 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated EMC7 data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher EMC7 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated EMC7 expression acts as an unfavorable survival marker.

CCRCC, LUAD, and UCEC are the cancer types where EMC7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.529	0.843	.002	26	view →
LUAD	DFS	Quartile	All	0.630	0.882	.004	7	view →
UCEC	DFS	Tertile	All	0.835	0.969	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

EMC7–CCRCC (DFS)

Open the CCRCC breakdown →